drugset

drugset / Trial / NCT04650321

Home Based Infusions for Ocrelizumab

NCT04650321 ↗

Phase 4 Recruiting 110 enrolled University of Colorado, Denver Genentech, Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

The goal is to assess the safety and effectiveness of home ocrelizumab infusion.

Timeline

Start: 2021-03-01
Primary completion: 2021-08-31
Completion: 2021-08-31

Publications

Results Vollmer TL, Cohen JA, Alvarez E, Nair KV, Boster A, Katz J, Pardo G, Pei J, Raut P, Merchant S, MacLean E, Pradhan A, Moss B. Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis. Mult Scler Relat Disord. 2020 Nov;46:102454. doi: 10.1016/j.msard.2020.102454. Epub 2020 Aug 18.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ocrelizumab	Monoclonal antibody	—	Intravenous

Indications